Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis

Who qualifies for our clinical trial?

Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis

blank

Introduction to RejuvenAir®

9 million Americans struggle with the debilitating symptoms of COPD with Chronic Bronchitis.1 The RejuvenAir System offers a unique solution that is aimed at treating the underlying cause of the disease; something no drug or device on the market does today.

The RejuvenAir System is a revolutionary cryosurgical device which applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient or same-day bronchoscopic procedure.

1. American Lung Association.

CAUTION: Investigational device. Limited by Federal law to investigational use.

About COPD with Chronic Bronchitis

Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).

Unlike common Bronchitis, which is acute and clears up quickly, Chronic Bronchitis (CB) is characterized by a long-term productive cough, breathlessness and/or wheezing as well as a tight chest sensation.

The persistent cough itself can be debilitating. Patients with Chronic Bronchitis often avoid social situations and give up activities, further contributing to a decline in overall well-being and quality of life.  While current medications help alleviate symptoms, they don’t address the underlying cause of the disease and are largely ineffective.

blank
blank
blank

How Metered Cryospray Works

In Chronic Bronchitis patients, the airways have been damaged. Cilia, the tiny hair-like cells lining the lungs that help move mucus and debris out of the airway, become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.

RejuvenAir rejuvenates the airways.

How Metered Cryospray Works

blank
blank

-196° C flash freeze causes instant cell death

blank

Preservation of extracellular matrix (ECM)

blank

Intact ECM enables healing with limited scarring and fibrosis

In Chronic Bronchitis patients, the airways have been damaged. Cilia, tiny hair-like cells lining the lungs that help move mucus and debris out of the airway become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.

RejuvenAir rejuvenates the airways.

The SPRAY-CB Clinical Trial

Researching a NEW option for people living with Chronic Bronchitis

The RejuvenAir System Trial for COPD with Chronic Bronchitis (SPRAY-CB) is currently recruiting patients in the United States. This trial is designed to continue to explore the safety and effectiveness of metered cryospray treatments in patients suffering from Chronic Bronchitis.

Find out more about the SPRAY-CB Trial

To find out if you or somebody you know might qualify, watch the video  then answer the short questionnaire below and register to continue the process.

Watch the video

Find out if you qualify:

Where the study is enrolling

The map below shows the study centers that are enrolling. For more information, refer to the ClinicalTrials.gov website.

Details are available for the United States SPRAY-CB Study and a smaller European Study.

The RejuvenAir System is CE marked in the European Union and limited to investigational use in the United States and is currently not for sale.

Title Address Description
Temple University, Philadelphia
1801 N Broad St, Philadelphia, PA 19122, USA

ENROLLING
Principal Investigator: Dr. G.J. Criner, Interventional Pulmonology /Pulmonary Care.

UC Davis Medical Center, Sacramento
2279 45th St, Sacramento, CA 95817, USA

ENROLLING
Principal Investigator: Dr. Ken Yoneda,  Interventional Pulmonology /Pulmonary Care

UT Southwestern Medical Center, Dallas
5939 Harry Hines Blvd, Dallas, TX 75390, USA

ENROLLING
Principal Investigator: Dr. Muhanned Abu-Hijleh,  Interventional Pulmonology /Pulmonary Care

El Camino Hospital, Mountain View
701 E El Camino Real, Mountain View, CA 94040, USA

ENROLLING
Principal Investigator: Dr. Ganesh Krishna,  Interventional Pulmonology /Pulmonary Care

Beth Israel Deaconess Medical Center, Boston
185 Pilgrim Rd, Boston, MA 02215, USA

ENROLLING
Principal Investigator: Dr. Adnan Majid,  Interventional Pulmonology /Pulmonary Care

Sarasota Memorial Hospital, Sarasota
1700 S Tamiami Trail, Sarasota, FL 34239, USA

ENROLLING
Principal Investigator: Dr. Joseph Seaman,  Interventional Pulmonology /Pulmonary Care

Medical University of South Carolina, Charleston
96 Jonathan Lucas St, Charleston, SC 29425, USA

ENROLLING
Principal Investigator: Dr. Charlie Strange,  Interventional Pulmonology /Pulmonary Care

Duke University School of Medicine, Durham
Durham, NC, USA

ENROLLING
Principal Investigator: Dr. Wahidi,  Interventional Pulmonology /Pulmonary Care

Advanced Pulmonary Research Institute, Loxahatchee
13005 Southern Blvd, Loxahatchee, FL 33470, USA

ENROLLING
Principal Investigator: Dr. Warshoff,  Interventional Pulmonology /Pulmonary Care

Cooper Health
New Brunswick, NJ, USA

ENROLLING
Principal Investigator: Dr. Wissam Abouzgheib, Bronchoscopy & Interventional Pulmonology

The Cleveland Clinic Foundation, Cleveland
9500 Euclid Ave, Cleveland, OH 44106, USA

ENROLLING
Principal Investigator: Dr. Gildea, Interventional Pulmonology /Pulmonary Care.

University Of Wisconsin Hospital, Madison
Highland Ave, Madison, WI, USA

ENROLLING
Principal Investigator: Dr. Ferguson, Interventional Pulmonology /Pulmonary Care

Louisiana State University Medical Center, Shreveport
Shreveport, LA 71103, USA

ENROLLING
Principal Investigator: Dr. Robert Holladay, Bronchoscopy & Interventional Pulmonology

University of Cincinnati, Cincinnati
Lindner Hall, 2925 Campus Green Dr, Cincinnati, OH 45221, USA

ENROLLING
Principal Investigator: Dr. Alejandro Adolfo Aragaki, Bronchoscopy & Interventional Pulmonology

St. David's Medical Center, Austin
1015 E 32nd St, Austin, TX 78705, USA

ENROLLING
Principal Investigator: Dr. D.  Dekeratry, Interventional Pulmonology

University of Maryland, Baltimore
Um Professional Bldg, 419 W Redwood St, Baltimore, MD 21201, USA

ENROLLING
Principal Investigator: Dr. Ashutosh Sachdeva, Interventional Pulmonology /Pulmonary Care.

Clinical Research Associates of Central PA
100 Hospital Ave, DuBois, PA 15801, USA

ENROLLING
Principal Investigator: Dr. Sandeep Bansal, Bronchoscopy & Interventional Pulmonology

Dartmouth-Hitchcock Medical Center, Lebanon
1 Medical Center Dr, Lebanon, NH 03766, USA

ENROLLING
Principal Investigator: Dr. David Feller-Hopman, Interventional Pulmonology /Pulmonary Care.

Prisma Health-Midlands, Columbia
Columbia, SC, USA

ENROLLING
Principal Investigator: Dr. W Tillis, Interventional Pulmonology /Pulmonary Care.

Ohio State University, Columbus
Davis Heart and Lung Research Institute, 473 W 12th Ave, Columbus, OH 43210, USA

ENROLLING
Principal Investigator: Dr. Christian Ghattas,  Interventional Pulmonology /Pulmonary Care

Spectrum Health, Grand Rapids
4100 Lake Dr SE, Grand Rapids, MI 49546, USA

ENROLLING
Principal Investigator: Dr. Cumbo-Nacelli,  Interventional Pulmonology /Pulmonary Care

HonorHealth, Scottsdale
Scottsdale, AZ, USA

NOW ENROLLING
Principal Investigator: Dr. Richard Sue,  Interventional Pulmonology /Pulmonary Care

Northwestern University
Rebecca Crown Center, 633 Clark St, Evanston, IL 60208, USA

NOT YET ENROLLING

Medical College of Wisconsin
8701 W Watertown Plank Rd, Wauwatosa, WI 53226, USA

NOT YET ENROLLING

blank

About Us

CSA Medical is committed to developing spray cryotherapy devices that improve the lives of people suffering from COPD with Chronic Bronchitis. We are advancing our core liquid nitrogen spray technology to target the underlying cause of Chronic Bronchitis – the over production of mucus and damaged cilia within the airways. By targeting and destroying these damaged cells without creating scar tissue, the body can begin the rapid regrowth of new, healthy normal functioning cells in the lung.

CSA Medical is currently conducting clinical studies with the RejuvenAir System. The clinical study aims to evaluate the effectiveness of the RejuvenAir System to reduce mucous production, cough, and inflammation in the Chronic Bronchitis patient population and to determine the extent of improvement in their overall health and quality of life.

blank

News & Resources

More news & resources…

Keep in touch

15 + 5 =

blank

131 Hartwell Avenue
Lexington
Massachusetts 02421

Phone: 781.538.4720
Toll Free: 866.481.7786
Fax: 866.300.5183
Email: info@rejuvenair.com

© 2020 CSA Medical, All Rights Reserved

CAUTION: Investigational device. Limited by Federal law to investigational use.

Pin It on Pinterest